In our view, the results obtained here and by other authors [34] indicate that SLC26A9 might actually improve the response to the correctors in people with CF carrying F508del-CFTR and possibly other class II mutations that respond to these drugs. The gene discussed is CFTR; the disease is cystic fibrosis.